CSL Seqirus Transitions to Trivalent Influenza Vaccines: Ins

CSL Seqirus Transitions to Trivalent Influenza Vaccines: Insights From Chief Health Officer Gregg Sylvester, MD

Discover the considerations behind CSL Seqirus' shift to trivalent influenza vaccines, removing B/Yamagata strain. Gregg Sylvester, MD, MPH, explains the impact on effectiveness and steps for a seamless transition in health care facilities.

Related Keywords

Gregg Sylvester , World Health Organization , Adobe Stock , Axel Kock , Infection Control ,